结论——在一些列nihss评分中的相应改变可以作为经静脉注射血栓溶解剂后一个简单的血管状态的临床指示器。
Conclusions - Relative changes in serial NIHSS scores can serve as a simple clinical indicator of arterial status after intravenous thrombolysis.
背景——经静脉注射血栓溶解剂后早期恢复可以在中风中发现，然而，有关评价临床治疗改善血管状态的益处的量表还未建立。
Background - Early recovery after intravenous thrombolysis can be observed in stroke; however, the utility of measuring clinical improvement to assess artery status has not been established.
一个好的溶纤剂能够溶解陈旧或新鲜的血栓，再栓塞率低。
A good thrombolytic drug could dissolve not only old thrombus but also new thrombus, and lower rate of thrombus formed again.
目的：综述溶血栓酶（促纤维蛋白溶解剂）在血栓中的临床应用概况，借以评价其疗效与安全性。
OBJECTIVE:To summarize the aspect of clinical usage on anticoagulant enzyme(fibrinolysis promoter), and evaluate their clinical efficacy and safety.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
应用推荐